Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.70 |
| ▸ | HTR7 | P34969 | 7/20 | 0.58 |
| ▸ | HTR1D | P28221 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR1E | P28566 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL790197 | 0.98 | SOS1 (0.68) | SOS1HTR7HTR1DHTR2AHTR2C | |
| SCHEMBL10818201 | 0.85 | HTR7 (0.79) | SOS1HTR7HTR1DHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL2258457 | 0.84 | HTR7 (0.77) | SOS1HTR7HTR1DHTR2AHTR2C | |
| SCHEMBL5644368 | 0.83 | HTR7 (0.80) | SOS1HTR7HTR1DHTR2AHTR2C | |
| SCHEMBL12340041 | 0.83 | SOS1 (1.00) | SOS1HTR7HTR1DHTR2AHTR2C | |
| SCHEMBL18934294 | 0.83 | HTR7 (0.80) | SOS1HTR7HTR1DHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL30785564 | 0.81 | HTR7 (0.78) | SOS1HTR7HTR1DHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL3441395 | 0.81 | SOS1 (0.97) | SOS1HTR7HTR1DHTR2AHTR2C | |
| SCHEMBL10818194 | 0.80 | SOS1 (0.69) | SOS1HTR7HTR1DHTR2AHTR2C | |
| SCHEMBL10817002 | 0.79 | SOS1 (0.68) | SOS1HTR7HTR1DHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2615916-B1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| US-5428169-A | Antidepressants, treating compulsive disorders, stuttering, trichotillomania | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5380847-A | Reaction of 1-methylpiperidine-4-hydrazine, ketone and titanium isopropoxide to form hydrazone | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0594001-A1 | Pyrazolo 4,3-c pyridines, a process for their preparation and their use as serotonin reuptake inhibitors | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5296491-A | Pyrazolo[4,3-c]pyridines and their use as serotonin reuptake inhibitors | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5264576-A | Antiserotonin agents, antidepressants and obsessive-compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0086422-B1 | PHARMACOLOGICALLY ACTIVE PYRAZOLO(4,3-C)PYRIDINES | GRUPPO LEPETIT S.p.A. (IT) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | SOS1 2795/4885HTR7 4347/4885HTR1D 4808/4885 |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | SOS1 1250/4885HTR7 3609/4885HTR1D 3822/4885 |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | SOS1 2795/4885HTR7 4347/4885HTR1D 4808/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | SOS1 2795/4885HTR7 4347/4885HTR1D 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.